Research Topics
Genomes and Genes | Lisa H ButterfieldSummaryAffiliation: University of Pittsburgh Country: USA Publications
| Collaborators
|
Detail Information
Publications
Spontaneous and vaccine induced AFP-specific T cell phenotypes in subjects with AFP-positive hepatocellular cancerLisa H Butterfield
Department of Medicine, Surgery and Immunology University of Pittsburgh Cancer Institute, University of Pittsburgh, Pittsburgh, PA 15213, USA
Cancer Immunol Immunother 56:1931-43. 2007....
Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanomaLisa H Butterfield
Department of Medicine, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA
J Immunother 31:294-309. 2008..Responses in CD8+ and CD4+ T cells to additional antigens were noted in 2 patients. The AdVMART1-transduced DC vaccine was safe and immunogenic in patients with metastatic melanoma...
Hierarchy of alpha fetoprotein (AFP)-specific T cell responses in subjects with AFP-positive hepatocellular cancerYang Liu
Department of Medicine, Division of Hematology/Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA
J Immunol 177:712-21. 2006..These subdominant epitope-specific T cells can also recognize tumor cells and may be important therapeutically...- AFP-specific CD4+ helper T-cell responses in healthy donors and HCC patientsViktoria N Evdokimova
Department of Medicine, Division of Hematology Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA
J Immunother 30:425-37. 2007..Importantly, CD4 T-cell cytokine expression profiles were skewed towards interleukin-2 and interferon-gamma production when activated by adenovirally engineered DC, which has therapeutic implications for vaccination efforts... - Antigen presentation by MART-1 adenovirus-transduced interleukin-10-polarized human monocyte-derived dendritic cellsShikhar Mehrotra
Department of Medicine, University of Connecticut School of Medicine, Farmington Avenue, Farmington, CT, USA
Immunology 113:472-81. 2004..These data suggest that although DCs generated in the presence of IL-10 tend to be non-immunogenic, they are capable of processing and presenting an antigen when the antigen is synthesized within the DC... - Regulation of antigen presentation machinery in human dendritic cells by recombinant adenovirusLazar Vujanovic
Department of Medicine, Division of Hematology Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA
Cancer Immunol Immunother 58:121-33. 2009..These data identify molecular changes in AdV-transduced DC (AdV/DC) that could influence T cell priming and should be considered in design of cancer vaccines... - Function but not phenotype of melanoma peptide-specific CD8(+) T cells correlate with survival in a multiepitope peptide vaccine trial (ECOG 1696)Carsten Schaefer
Department of Pathology, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA
Int J Cancer 131:874-84. 2012..Phenotypic analyses of CD8(+) tet(+) T cells did not correlate with clinical responses to the vaccine, indicating that functional assessments of peptide-specific T cells are preferable for monitoring of anti-tumor vaccines... - Virally infected and matured human dendritic cells activate natural killer cells via cooperative activity of plasma membrane-bound TNF and IL-15Lazar Vujanovic
Department of Pathology and Immunology, University of Pittsburgh, Hillman Cancer Center, 5117 Centre Ave, Pittsburgh, PA 15213, USA
Blood 116:575-83. 2010..These findings demonstrate that both Ad.DCs and mDCs can efficiently promote innate immune functions by activation of NK cells through the cooperative activities of tmTNF and trans-IL-15 mediated by cell-to-cell contact... - Immunotherapy of cancer in 2012John M Kirkwood
Melanoma and Skin Cancer Program, University of Pittsburgh Cancer Institute, Hillman Cancer Center, Pittsburgh, PA 15213, USA
CA Cancer J Clin 62:309-35. 2012.... - New approaches to the development of adenoviral dendritic cell vaccines in melanomaLisa H Butterfield
University of Pittsburgh, Cancer Institute, and Department of Medicine, Hillman Cancer Center, 5117 Centre Avenue, Pittsburgh, PA 15213, USA
Curr Opin Investig Drugs 11:1399-408. 2010..Interactions between AdVs and DCs, initial clinical trial results, and new developments in DC engineering and in AdV biology are reviewed... - Enhanced tumor responses to dendritic cells in the absence of CD8-positive cellsAntoni Ribas
Department of Medicine, Division of Hematology Oncology, University of California, Los Angeles, CA 90095, USA
J Immunol 172:4762-9. 2004..Elucidation of the signaling events that activate these effective cytotoxic cells and the putative suppressive mechanisms in a wild-type environment may provide means to enhance the clinical activity of DC-based approaches... - Differing patterns of circulating regulatory T cells and myeloid-derived suppressor cells in metastatic melanoma patients receiving anti-CTLA4 antibody and interferon-α or TLR-9 agonist and GM-CSF with peptide vaccinationAhmad A Tarhini
University of Pittsburgh Cancer Institute, UPMC Cancer Pavilion, Pittsburgh, PA 15232, USA
J Immunother 35:702-10. 2012..T-reg findings suggest that IFN/treme induced clinically significant antitumor responses by inhibiting CTLA4 suppressive effects on T effectors, and less so by affecting T-reg... - Recent advances in immunotherapy for hepatocellular cancerLisa H Butterfield
Department of Medicine, Universtiy of Pittsburgh, Medical School, Pittsburgh, USA
Swiss Med Wkly 137:83-90. 2007..These trials, testing novel immune-based interventions in HCC subjects, have resulted in immunological responses and some have impacted recurrence and survival of HCC subjects... - Immunotherapeutic strategies for hepatocellular carcinomaLisa H Butterfield
Departments of Medicine, Surgery and Immunology, University of Pittsburgh, Hillman Cancer Center, Research Pavilion, Room 1 19, 5117 Centre Avenue, Pittsburgh, Pennsylvania 15213, USA
Gastroenterology 127:S232-41. 2004..These trials, testing novel immune-based interventions in HCC subjects, have resulted in immunologic responses and have impacted recurrence and survival in HCC subjects... - Dendritic cells in cancer immunotherapy: vaccines or autologous transplants?Pawel Kalinski
Department of Surgery, University of Pittsburgh, Pittsburgh, PA 15213 1863, USA
Immunol Res 50:235-47. 2011.... - Dendritic cell-based vaccines positively impact natural killer and regulatory T cells in hepatocellular carcinoma patientsSarah M Bray
Department of Medicine, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA
Clin Dev Immunol 2011:249281. 2011..We also extend these data by testing several forms of DC vaccines in vitro to determine the impact of antigen loading and maturation signals on both NK cells and Treg from healthy donors and HCC patients... - Ectopic T-bet expression licenses dendritic cells for IL-12-independent priming of type 1 T cells in vitroMichael W Lipscomb
Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
J Immunol 183:7250-8. 2009..Tbets promote improved type 1 functional polarization from naive T cell responders. Given their superior type 1 polarizing capacity, DC.Tbet may be suitable for use in vaccines designed to prevent/treat cancer or infectious disease... - Melanoma cancer vaccines and anti-tumor T cell responsesLazar Vujanovic
Division of Hematology Oncology, Department of Medicine, University of Pittsburgh Cancer Institute, University of Pittsburgh, Pennsylvania 15213, USA
J Cell Biochem 102:301-10. 2007.... - A phase I/II trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four alpha-fetoprotein peptidesLisa H Butterfield
Department of Medicine, Surgery and Immunology, Hillman Cancer Center, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania 15213, USA
Clin Cancer Res 12:2817-25. 2006..We conclude that the human T cell repertoire is capable of responding to the AFP self antigen after the administration of AFP peptide-pulsed DC even in an environment of high circulating levels of this oncofetal antigen... - Immunogenicity and antitumor effects of vaccination with peptide vaccine+/-granulocyte-monocyte colony-stimulating factor and/or IFN-alpha2b in advanced metastatic melanoma: Eastern Cooperative Oncology Group Phase II Trial E1696John M Kirkwood
Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania 15213 2584, USA
Clin Cancer Res 15:1443-51. 2009.... - Current developments in cancer vaccines and cellular immunotherapyAntoni Ribas
Division of Hematology Oncology, Department of Medicine, University of California Los Angeles, 90095 1782, USA
J Clin Oncol 21:2415-32. 2003.... - Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in Hideho Okada
G12 a Research Pavilion at the Hillman Cancer Center, 5117 Centre Ave, Pittsburgh, PA 15213 1863, USA
J Clin Oncol 29:330-6. 2011..GAAs for these peptides are EphA2, interleukin (IL)-13 receptor-α2, YKL-40, and gp100... - Multiplex serum biomarker assessments: technical and biostatistical issuesLisa H Butterfield
University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA
J Transl Med 9:173. 2011..Many of these studies seek biomarkers among circulating proteins accessed in blood. Many levels of standardization in materials and procedures have been identified which can impact the resulting data... - Development of a potency assay for human dendritic cells: IL-12p70 productionLisa H Butterfield
Department of Medicine, Surgery and Immunology, University of Pittsburgh School of Medicine and University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA
J Immunother 31:89-100. 2008..It defines the stability of DC vaccines. It's application to DC assessments in several on-going early-phase clinical trials is expected to provide data defining the assay value in predicting in vivo efficacy of DC-based vaccines... - Pitfalls in retrospective analyses of biomarkers: a case study with metastatic melanoma patientsDouglas M Potter
Biostatistics Facility, University of Pittsburgh Cancer Institute, 201 North Craig Street, Suite 325, Pittsburgh, PA 15213, United States
J Immunol Methods 376:108-12. 2012..We describe a new study of the association of serum biomarker level with overall survival in melanoma patients, and the problems encountered in carrying it out... - Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy BiomarkersLisa H Butterfield
Department of Medicine, University of Pittsburgh, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania 15213, USA
Clin Cancer Res 17:3064-76. 2011..Despite substantial effort, we do not yet know which parameters of antitumor immunity to measure and which assays are optimal for those measurements... - Immuno-oncology biomarkers 2010 and beyond: perspectives from the iSBTc/SITC biomarker task forceLisa H Butterfield
Departments of Medicine, Surgery and Immunology, University of Pittsburgh, Pittsburgh, PA, USA
J Transl Med 8:130. 2010..The presentations are summarized in this report; additional program information and slides are available online at the iSBTc/SITC website... - Alpha-fetoprotein and other tumour-associated antigens for immunotherapy of hepatocellular cancerViktoria N Evdokimova
University of Pittsburgh, Hillman Cancer Center, Department of Medicine, Hematology Oncology, Research Pavilion, Room 1 32, 5117 Centre Avenue, Pittsburgh, PA 15213, USA
Expert Opin Biol Ther 8:325-36. 2008..Hepatocellular carcinoma (HCC) is a leading cause of cancer death, with few treatment options for advanced disease... - Spontaneous immune responses against glioma-associated antigens in a long term survivor with malignant gliomaRyo Ueda
Department of Neurological Surgery, University of Pittsburgh School of Medicine, 200 Lothrop Street, Pittsburgh, PA 15213, USA
J Transl Med 5:68. 2007..In this report, we characterized GAA-specific CD8+ T cells and innate immune cells in a patient who has survived with anaplastic astrocytoma (AA) for over 12 years without recurrence... - Next generation of immunotherapy for melanomaJohn M Kirkwood
Hillman Cancer Center, Research Pavilion, Suite 1 32, 5117 Centre Ave, Pittsburgh, PA 15213 2584, USA
J Clin Oncol 26:3445-55. 2008..Immunotherapy has a long history with striking but limited success in patients with melanoma. To date, interleukin-2 and interferon-alfa2b are the only approved immunotherapeutic agents for melanoma in the United States... - Intratumoral IL-12 gene therapy results in the crosspriming of Tc1 cells reactive against tumor-associated stromal antigensXi Zhao
Department of Dermatology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213, USA
Mol Ther 19:805-14. 2011..These TASA and their derivative peptides may prove useful in vaccine formulations against solid cancers, as well as, in the immune monitoring of HLA-A2(+) cancer patients receiving therapeutic interventions, such as IL-12 gene therapy... - Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of patients with malignant gliomasHideho Okada
Department of Neurological Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
J Transl Med 5:67. 2007..The prognosis for malignant gliomas remains dismal. We addressed the safety, feasibility and preliminary clinical activity of the vaccinations using autologous glioma cells and interleukin (IL)-4 gene transfected fibroblasts... - T-cell responses to HLA-A*0201 immunodominant peptides derived from alpha-fetoprotein in patients with hepatocellular cancerLisa H Butterfield
Division of Surgical Oncology, University of California at Los Angeles, Los Angeles, California, USA
Clin Cancer Res 9:5902-8. 2003..We wished to test the hypothesis that AFP peptide-reactive T cells could be expanded in vivo in HCC patients immunized with these four AFP peptides... - The Immunotherapeutics & Vaccine Summit--CHI's fourth annual meeting. Preclinical/clinical development of immunotherapies and vaccines. 17-19 August 2009, Providence, RI, USALisa H Butterfield
University of Pittsburgh, Hillman Cancer Center, 5117 Centre Avenue, Pittsburgh, PA 15213, USA
IDrugs 12:633-5. 2009..Investigational vaccines discussed include a fusion protein adjuvant vaccine (Research by Discovery), a novel intradermal particle delivery device (Université de Sherbrooke) and a Hsp-based vaccine for meningitis (ImmunoBiology Ltd)... - Determinant spreading and tumor responses after peptide-based cancer immunotherapyAntoni Ribas
Department of Medicine, 54 140 CHS, UCLA Medical Center, 10833 Le Conte Avenue, Los Angeles, CA 90095 1782, USA
Trends Immunol 24:58-61. 2003.... - Regulation of melanoma epitope-specific cytolytic T lymphocyte response by immature and activated dendritic cells, in vitroShikhar Mehrotra
Department of Medicine, University of Connecticut School of Medicine, Farmington, Connecticut 06030, USA
Cancer Res 63:5607-14. 2003..These observations, therefore, have implications on the DC-based cancer vaccine designs and are relevant in the inquiry into the role of DCs on tolerance induction... - A short course of neoadjuvant IRX-2 induces changes in peripheral blood lymphocyte subsets of patients with head and neck squamous cell carcinomaTheresa L Whiteside
Research Pavilion at the Hillman Cancer Center, University of Pittsburgh Cancer Institute, 5117 Centre Avenue, Pittsburgh, PA 15213 1863, USA
Cancer Immunol Immunother 61:783-8. 2012..2011). In the same patients enrolled in the Phase II study, peripheral blood lymphocyte subsets were monitored pre- and post-IRX-2 therapy to evaluate changes induced by IRX-2... - Zinc in innate and adaptive tumor immunityErica John
Department of Surgery, University of Pittsburgh, 200 Lothrop Street, Pittsburgh, PA 15213, USA
J Transl Med 8:118. 2010..Based on this novel synthesis, approaches which locally regulate zinc levels to promote survival of immune cells and/or induce tumor apoptosis are in order... - A systematic approach to biomarker discovery; preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers"Lisa H Butterfield
Department of Medicine, Division of Hematology Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, 15213, USA
J Transl Med 6:81. 2008..This foreword provides an overview of the task force and invites feedback from readers that might be incorporated in the discussions and in the final document... - Cancer-related symptom clusters, eosinophils, and survival in hepatobiliary cancer: an exploratory studyJennifer L Steel
Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213, USA
J Pain Symptom Manage 39:859-71. 2010..The study of symptom clusters is gaining increased attention in the field of oncology in an attempt to improve the quality of life of patients diagnosed with cancer... - Activation of antigen-presenting cells by DNA delivery vectorsWilson S Meng
Duquesne University, Division of Pharmaceutical Sciences, 600 Forbes Ave, Pittsburgh, PA 15282, USA
Expert Opin Biol Ther 5:1019-28. 2005..This paper will summarise recent reports of adjuvant properties of viral and non-viral delivery systems... - Rational design of peptide-based tumor vaccinesWilson S Meng
Division of Pharmaceutical Sciences, Duquesne University, Mylan School of Pharmacy, Pittsburgh, Pennsylvania 15282, USA
Pharm Res 19:926-32. 2002..This review will discuss the basic and clinical aspects of modifying native TAA peptides as tumor vaccines... - Immunosuppressive effects of interleukin-12 coexpression in melanoma antigen gene-modified dendritic cell vaccinesAntoni Ribas
Department of Surgery, University of California at Los Angeles, 90095-1782, USA
Cancer Gene Ther 9:875-83. 2002..In conclusion, in this animal model, IL-12 production by gene-modified DC leads to a cytokine-induced dose-dependent inhibition of antigen-specific antitumor protection... - Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanomaLisa H Butterfield
Department of Surgery, Division of Surgical Oncology, UCLA Jonsson Comprehensive Cancer Center, University of California at Los Angeles, 10833 Le Conte Avenue, Los Angeles, CA 90095-1782, USA
Clin Cancer Res 9:998-1008. 2003.... - Immunotherapy of hepatocellular carcinomaLisa H Butterfield
Department of Surgery, Division of Surgical Oncology, University of California, Los Angeles, CA 90095, USA
Expert Opin Biol Ther 2:123-33. 2002..The most recent data supporting the use of immunotherapy for hepatocellular cancer is reviewed in detail... - Human dendritic cell maturation by adenovirus transduction enhances tumor antigen-specific T-cell responsesLana Schumacher
Division of Surgical Oncology, UCLA Medical Center, University of California Los Angeles, USA
J Immunother (1997) 27:191-200. 2004..This study has important implications for the design of DC-based clinical trials... - Ionizing radiation affects human MART-1 melanoma antigen processing and presentation by dendritic cellsYu-Pei Liao
Department of Radiation Oncology, Division of Surgical Oncology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA
J Immunol 173:2462-9. 2004..1/K(b) transgenic mice. Taken together, these results suggest that radiation modulates MHC class I-mediated antitumor immunity by functionally affecting DC Ag presentation pathways... - Surveillance of the eye and vision in a clinical trial of MART1-transformed dendritic cells for metastatic melanomaLynn K Gordon
Department of Ophthalmology, and the Jules Stein Eye Institute, and the UCLA Jonsson Comprehensive Cancer Center, University of California at Los Angeles, 100 Stein Plaza, Los Angeles, CA 90095-7000, USA
Control Clin Trials 25:400-7. 2004..Therefore, surveillance of the eye and vision should be considered in melanoma immunotherapy trials... - Role of dendritic cell phenotype, determinant spreading, and negative costimulatory blockade in dendritic cell-based melanoma immunotherapyAntoni Ribas
Department of Surgery, Division of Surgical Oncology, UCLA Jonsson Comprehensive Cancer Center, University of California at Los Angeles, Los Angeles, California, USA
J Immunother (1997) 27:354-67. 2004..Sequential CTLA4 blockade may enhance the immune activity of DC-based immunotherapy... - Natural killer cells play a critical role in the immune response following immunization with melanoma-antigen-engineered dendritic cellsJennifer A Wargo
Department of Surgery, Division of Surgical Oncology, University of California at Los Angeles, Los Angeles, CA 90095, USA
Cancer Gene Ther 12:516-27. 2005..In conclusion, protective immunity after tumor antigen gene-modified DC immunization requires collaboration between CD4+ and CD8+ T cells and NK cells... - Cancer immunotherapy using gene-modified dendritic cellsAntoni Ribas
Departments of Surgery, Medicine, Division of Hematology Oncology, 11 934 Factor Bldg UCLA Medical Center, 10833 Le Conte Avenue, Los Angeles, CA 90095 1782, USA
Curr Gene Ther 2:57-78. 2002..These data may help in the translation of this promising approach to the clinic...